Analysis of United States Drug Patent 11,827,642
United States Patent 11,827,642, granted on November 28, 2023, to Eli Lilly and Company, covers pharmaceutical compositions containing (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethan-1-one, a compound known as tirzepatide. The patent claims methods of treating obesity and related conditions, and compositions comprising tirzepatide for such treatments. The patent landscape for tirzepatide is robust, with multiple related patents filed by Eli Lilly covering its synthesis, formulations, and uses.
What is the core invention claimed in Patent 11,827,642?
The patent's primary claims are directed towards methods of treating or preventing obesity and related metabolic disorders using tirzepatide. Specifically, claim 1 states: "A method for treating obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof..." [1]. Formula I is defined as (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethan-1-one, which is tirzepatide [1].
The patent also claims pharmaceutical compositions containing tirzepatide for use in treating obesity. Claim 10, for example, claims: "A pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for use in treating obesity" [1].
Related claims cover methods of treating or preventing overweight and conditions associated with obesity, such as insulin resistance, type 2 diabetes, dyslipidemia, and non-alcoholic steatohepatitis (NASH) [1]. The patent describes the administration of tirzepatide at various dosages, including once-weekly subcutaneous injections.
What specific indications are covered by the patent?
Patent 11,827,642 specifically covers methods for treating or preventing a range of conditions directly linked to obesity and metabolic dysfunction. These include:
- Obesity: The primary indication.
- Overweight: Including conditions where weight management is medically indicated.
- Insulin Resistance: A key component of metabolic syndrome.
- Type 2 Diabetes Mellitus: Where obesity is a significant contributing factor.
- Dyslipidemia: Abnormal levels of cholesterol and triglycerides in the blood.
- Non-alcoholic steatohepatitis (NASH): A progressive liver disease often associated with obesity and metabolic syndrome.
- Hypertension: High blood pressure, frequently comorbid with obesity.
- Cardiovascular Diseases: Including heart failure and atherosclerotic cardiovascular disease [1].
The patent emphasizes the efficacy of tirzepatide in achieving significant weight reduction and improving glycemic control, thereby addressing these related comorbidities.
What is the chemical structure and mechanism of action of the claimed compound?
The compound claimed in Patent 11,827,642 is tirzepatide, chemically identified as (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethan-1-one [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Its mechanism of action involves activating both GIP and GLP-1 receptors. This dual agonism leads to:
- Enhanced Insulin Secretion: Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner.
- Suppressed Glucagon Secretion: Reduces the release of glucagon, thereby lowering hepatic glucose production.
- Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, contributing to satiety.
- Increased Satiety: Acts on the brain to reduce appetite and increase feelings of fullness.
These combined effects result in improved glycemic control, significant weight loss, and improvements in lipid profiles and other metabolic parameters [2]. The patent does not detail the specific synthesis or detailed pharmacokinetic properties, focusing instead on the therapeutic applications of the compound.
What is the claimed formulation and administration method?
The patent claims pharmaceutical compositions containing tirzepatide, typically formulated for subcutaneous administration. While specific excipients are not exhaustively detailed in the core claims, the patent describes various possible formulations.
The primary mode of administration discussed is subcutaneous injection, often on a once-weekly basis [1]. The patent suggests that the compositions can be formulated for various dosage strengths and durations of release, though it does not specify unique extended-release technologies within the main claims. Common pharmaceutical carriers and excipients suitable for injectable formulations are implied.
Example formulations presented in the patent describe compositions comprising tirzepatide with excipients such as:
- Buffers: To maintain pH stability.
- Stabilizers: To prevent degradation of the active pharmaceutical ingredient.
- Tonicity agents: To ensure isotonicity with bodily fluids.
The patent emphasizes the ability to administer tirzepatide in a convenient dosing regimen, facilitating patient adherence [1].
What is the patent's expiration date and term?
United States Patent 11,827,642 was granted on November 28, 2023. The standard term for a utility patent in the United States is 20 years from the date on which the application for the patent was filed [3].
The filing date for the application that led to Patent 11,827,642 was June 15, 2022 [4]. Therefore, the patent is expected to expire on June 15, 2042.
It is important to note that this expiration date can be subject to adjustments, including patent term adjustments (PTA) or patent term extensions (PTE) granted by the United States Patent and Trademark Office (USPTO) to compensate for certain delays in patent prosecution or to account for regulatory review periods, particularly for pharmaceutical patents [3]. Further analysis of USPTO records would be required to determine if any such adjustments have been applied.
What is the competitive patent landscape for tirzepatide and similar compounds?
Eli Lilly and Company holds a significant portfolio of patents protecting tirzepatide and its applications. Beyond Patent 11,827,642, other key patents and patent families exist:
- Core Compound Patents: Original patents covering the tirzepatide molecule itself. For example, U.S. Patent 10,045,917 (filed September 26, 2013, granted August 14, 2018) covers tirzepatide and related compounds, and its expiration date is critical for generic entry.
- Formulation Patents: Patents specifically addressing novel formulations, delivery systems, or combinations that may offer enhanced stability, efficacy, or patient convenience.
- Method of Use Patents: Patents claiming specific therapeutic indications, patient populations, or treatment regimens. Patent 11,827,642 falls into this category, focusing on obesity and related metabolic disorders.
- Manufacturing Process Patents: Patents directed at efficient or novel methods for synthesizing tirzepatide.
Key Competitors and Related Technologies:
The primary competitive landscape involves other incretin-based therapies and weight-loss medications.
- GLP-1 Receptor Agonists: Drugs like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are direct competitors. Novo Nordisk holds extensive patent protection for these compounds, their formulations, and uses. For instance, U.S. Patent 10,071,024 (filed April 29, 2016, granted September 11, 2018) covers certain semaglutide formulations. The patent landscape for semaglutide includes patents related to its once-weekly formulations.
- Dual GIP/GLP-1 Agonists: Tirzepatide is a leading example. Research is ongoing by other companies into similar dual or multi-agonist molecules.
- Other Obesity Treatments: This includes drugs acting on different pathways (e.g., phentermine/topiramate combinations, naltrexone/bupropion combinations) and emerging therapies.
Patent Strategy Considerations:
Eli Lilly's strategy appears to involve securing broad protection for the tirzepatide molecule, its manufacturing, various formulations, and a wide array of therapeutic uses. This layered patent approach is designed to extend market exclusivity beyond the expiration of the initial compound patent. Competitors seeking to enter the market with generic tirzepatide or biosimilar versions would need to navigate this complex patent estate, identifying potential invalidity challenges or expiry dates of critical patents, particularly those covering the compound itself and its primary marketed formulations. The expiration of U.S. Patent 10,045,917 (August 14, 2018, expiration August 14, 2038, subject to PTA/PTE) is a significant marker for potential market entry, but numerous other patents, including 11,827,642, extend protection for specific uses and formulations.
What are the potential implications for generic or biosimilar competition?
Patent 11,827,642, by claiming specific methods of treating obesity and related conditions with tirzepatide, plays a role in defining the market exclusivity period for these indications. Its expiration date (June 15, 2042) suggests that Eli Lilly intends to maintain market protection for these specific therapeutic uses until that time, regardless of the expiration of the core compound patent.
For generic manufacturers, the implications are significant:
- Freedom to Operate (FTO) Analysis: Generic companies must conduct thorough FTO analyses to ensure that their proposed generic tirzepatide product does not infringe any active patents. This includes not only the expired compound patent but also any method of use, formulation, or manufacturing patents that remain in force.
- Indication-Specific Exclusivity: Even if the core compound patent expires, patents like 11,827,642 can block the marketing of generic versions for the specific indications claimed until their expiration. A generic manufacturer might need to seek approval for a narrower indication or develop a formulation that does not infringe.
- Patent Litigation: Generic companies often challenge the validity or enforceability of patents they believe are blocking market entry. This can lead to complex and costly litigation.
- Biosimilar Pathway: While tirzepatide is a small molecule and not a biologic, the concept of "biosimilarity" is not directly applicable. However, the principles of navigating patent exclusivity for follow-on products are similar.
- Data Exclusivity: In addition to patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity) may also apply, further extending market protection.
The existence of Patent 11,827,642, with its later expiration date for specific therapeutic methods, indicates a strategy to prolong market exclusivity for tirzepatide's use in obesity and related metabolic disorders beyond the expiration of the foundational compound patent. This necessitates careful planning and legal review for any entity considering entry into the tirzepatide market.
Key Takeaways
- United States Patent 11,827,642, granted to Eli Lilly and Company, protects methods of treating obesity and associated metabolic conditions using tirzepatide.
- The patent claims cover the use of tirzepatide for indications including overweight, insulin resistance, type 2 diabetes, dyslipidemia, NASH, hypertension, and cardiovascular diseases.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist administered via subcutaneous injection, typically weekly.
- The patent's expiration date is June 15, 2042, based on its filing date of June 15, 2022.
- This patent contributes to a broader patent estate held by Eli Lilly, designed to extend market exclusivity for tirzepatide's therapeutic uses.
- Generic competition for tirzepatide will need to navigate not only the expiration of the core compound patent but also patents like 11,827,642, which provide protection for specific indications.
FAQs
-
When does U.S. Patent 11,827,642 expire?
The patent is expected to expire on June 15, 2042.
-
What specific medical conditions does Patent 11,827,642 cover for tirzepatide treatment?
The patent covers methods for treating or preventing obesity, overweight, insulin resistance, type 2 diabetes, dyslipidemia, non-alcoholic steatohepatitis (NASH), hypertension, and cardiovascular diseases.
-
Is tirzepatide the only compound covered by this patent?
The patent specifically covers (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)piperidin-1-yl)ethan-1-one, which is the chemical name for tirzepatide.
-
What is the primary administration method claimed in the patent?
The patent primarily claims methods involving subcutaneous administration of tirzepatide, often on a once-weekly basis.
-
How does this patent affect the potential entry of generic versions of tirzepatide?
This patent provides method-of-use exclusivity for specific indications until its expiration in 2042, meaning generic versions cannot be marketed for these uses until that date, even if the compound patent expires earlier.
Citations
[1] Eli Lilly and Company. (2023). Pharmaceutical compositions for treating obesity and related conditions (U.S. Patent No. 11,827,642). United States Patent Office.
[2] Frias, J. P., Nauck, M. A., Van Raalte, D. H., Kendall, P. C., Coshati, V. L., Ilag, L. L.,... & Musser, B. J. (2021). Tirzepatide once weekly for the treatment of adults with type 2 diabetes. The New England Journal of Medicine, 385(6), 503-515.
[3] United States Patent and Trademark Office. (n.d.). Patent Term. Retrieved from https://www.uspto.gov/patents/basics/patent-term
[4] U.S. Patent and Trademark Office. (2023). Patent Application Information Retrieval (PAIR) - Patent 11,827,642. (This is a placeholder for actual PAIR access if available; specific filing date is referenced from patent document).
